TheraRadar
Data updated: May 26, 2026

DEXEDRINE SPANSULE (dextroamphetamine sulfate)

CNS Approved 1976-08-02

DEXEDRINE SPANSULE is indicated for the treatment of Narcolepsy; Attention Deficit Hyperactivity Disorder.

Source: FDA Label • IMPAX LABS INC
1
Indication
--
Phase 3 Trials
49
Years on Market

Details

Status
Prescription
First Approved
1976-08-02
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: DEXTROAMPHETAMINE SULFATE

DEXEDRINE SPANSULE Approval History

1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
123 FDA actions from 1976 to 2025
Sep 2025 SUPPL
Label · Labeling
Oct 2023 SUPPL
Label · Labeling
Feb 2022 SUPPL
Label · Labeling

What DEXEDRINE SPANSULE Treats

2 indications

DEXEDRINE SPANSULE is approved for 2 conditions since its original approval in 1976. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Narcolepsy
  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

DEXEDRINE SPANSULE Boxed Warning

ABUSE, MISUSE, AND ADDICTION DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death [see Overdosage ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DEXEDRINE, assess each patient’s risk for abuse, misuse, and addiction. Educate patients...

DEXEDRINE SPANSULE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DEXEDRINE SPANSULE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
2 shared
Takeda
ADDERALL XR 15
AMPHETAMINE ASPARTATE
2 shared
Takeda
ADDERALL XR 20
AMPHETAMINE ASPARTATE
2 shared
Takeda
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEXEDRINE SPANSULE FDA Label Details

Indications & Usage

FDA Label (PDF)

DEXEDRINE SPANSULE is indicated for the treatment of Narcolepsy; Attention Deficit Hyperactivity Disorder.

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE, AND ADDICTION DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death [see Overdosage ] , and this risk i...

Track DEXEDRINE SPANSULE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.